Literature DB >> 28387319

Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care.

Melanie J Davies1, Sudesna Chatterjee1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28387319     DOI： 10.1038/nrendo.2017.41

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

1.  Improving primary care for patients with chronic illness.

Authors:  Thomas Bodenheimer; Edward H Wagner; Kevin Grumbach
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

2.  Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.

Authors:  Melanie J Davies; Divina Glah; Barrie Chubb; Gerasimos Konidaris; Phil McEwan
Journal:  Pharmacoeconomics       Date:  2016-09       Impact factor: 4.981

3.  Telemedicine in the Management of Type 2 Diabetes Mellitus.

Authors:  Guixia Wang; Zhengyun Zhang; Yakun Feng; Lin Sun; Xianchao Xiao; Gang Wang; Yuan Gao; Huan Wang; Hong Zhang; Yufeng Deng; Chenglin Sun
Journal:  Am J Med Sci       Date:  2016-10-27       Impact factor: 2.378

4.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

Review 5.  Minimizing Hypoglycemia in Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2015-08       Impact factor: 19.112

6.  Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

Authors:  Julio Rosenstock; Ronnie Aronson; George Grunberger; Markolf Hanefeld; PierMarco Piatti; Pierre Serusclat; Xi Cheng; Tianyue Zhou; Elisabeth Niemoeller; Elisabeth Souhami; Melanie Davies
Journal:  Diabetes Care       Date:  2016-08-15       Impact factor: 19.112

7.  Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial.

Authors:  John Furler; David O'Neal; Jane Speight; Jo-Anne Manski-Nankervis; Alexandra Gorelik; Elizabeth Holmes-Truscott; Louise Ginnivan; Doris Young; James Best; Elizabeth Patterson; Danny Liew; Leonie Segal; Carl May; Irene Blackberry
Journal:  BMJ       Date:  2017-03-08

8.  Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes.

Authors:  Sanjoy K Paul; Kerenaftali Klein; Brian L Thorsted; Michael L Wolden; Kamlesh Khunti
Journal:  Cardiovasc Diabetol       Date:  2015-08-07       Impact factor: 9.951

9.  Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants.

Authors: 
Journal:  Lancet       Date:  2016-04-06       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.